Article Text

Download PDFPDF
OC-101 Lymph node positivity in patients with anal cancer treated in the modern era: prognostic impact and patterns of locoregional relapse (L‐nuance)
  1. H Sekhar1,2,
  2. R Kochhar1,
  3. L Malcomson2,
  4. MP Saunders1,
  5. B Chakrabarty1,
  6. PE Fulford1,
  7. MS Wilson1,
  8. ST O’Dwyer1,
  9. AG Renehan1,2
  1. 1Anal Cancer MDT, The Christie, NHS Foundation Trust
  2. 2University of Manchester, Manchester, UK


Introduction Chemo-radiotherapy (CRT) is the first line treatment in patients with anal squamous cell carcinoma (ASCC). Clinical lymph node positivity (LN+) is considered an adverse prognosticator. Accurate lymph node staging impacts on treatment, such that in LN+ patients, lymphatic fields are treated with prophylactic phase I wide volume radiotherapy. Modern imaging modalities, namely magnetic resonance imaging (MRI) and PET-CT scanning increase sensitivity to detect LN+, but It is unclear whether enhanced pre-treatment staging impacts upon oncological outcome.

Method From 1990 to 2014 we characterised the pattern of changes in the detection rates of LN+ in patients with ASCC through a dedicated anal cancer MDT serving a population of 3 million. We divided time periods as: (i) pre-MRI era; (ii) MRI era; and (iii) MRI + PET-CT era. In patients receiving curative CRT, we determined actuarial rates for loco-regional and inguinal relapses, and cancer-specific survival (CSS), using Kaplan-Meier curves. Imaging modalities were compared using log-rank tests, and Cox multivariate models that also conditioned for period and cohort effects.

Results From 971 patients with new ASSC, 550 were treated with CRT [M, F: 207:343, median age (range): 61 (29–89)]. In the pre-MRI era (pre-2004), LN+ was identified in 18% (36/200); with the use of MRI the detection rate increased to 34% (62/185); and further increased to 48% (58/120) with the use of MRI and PET-CT in combination (post-2011) (p < 0.001). In multivariate models, T stage was the only other independent determinant of LN+ (T1 2% (1/55) vs T4 55% (55/100), p < 0.001). The secular trends were associated with an altered prognostic profile. For the pre-MRI era the 5 year survival of LN+ and LN- was 51% and 78%; for the post-MRI era the 5 year survival was 75% and 85% for LN+ and LN- respectively. Additionally, there was loss of discrimination between the two prognostic categories with the significant difference in survival between the groups during the pre-MRI era being lost in the MRI-era (p = 0.0014 and 0.089 respectively) – a Will Roger phenomenon. There were minor improvements in 3-year loco-regional relapse rates over the time periods. The overall rate of inguinal nodal relapse was low (3%).

Conclusion MRI and PET scans improve pre-treatment staging in anal cancer although precise characterisation of the specific lymphatic fields involved needs further evaluation. Demonstration of the Will Roger’s effect challenges the prognostic value of pre-treatment nodal status in anal cancer and current treatment algorithms. This study was generously supported by the BDRF.

Disclosure of interest None Declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.